Business
Castle Biosciences Announces Publication of a Study Evaluating Incorporation of DecisionDx-SCC into Management of High-Risk Cutaneous Squamous Cell Carcinoma
Published Recently in Current Medical Research and Opinion FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer
About this update from Castle Biosciences, Inc.
[{"type":"text","content":"\nPublished Recently in Current Medical Research and Opinion\n\n FRIENDSWOOD, Texas--(BUSINESS WIRE)--\nCastle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the publication of a clinical utility model for its cutaneous squamous cell carcinoma (SCC) prognostic test, DecisionDx®-SCC, for patients diagnosed with high-risk cutaneous SCC. The test is expected to launch commercially in the second half of 2020.\n\n\nThe article titled, “Integrating gene expression profiling into NCCN high-risk cutaneous squamous cell carcinoma management recommendations: impact on patient management,” was published in the peer-reviewed journal, Current Medical Research and Opinion (CMRO).\n\n\nThis publication proposes a framework for integration of DecisionDx-SCC into existing management pathways for a risk-appropriate approach in high-risk cutaneous SCC patients (as defined by having one or more high-risk factors and consistent with the National Comprehensive Cancer Network (NCCN) guidelines).\n\n\n“Castle’s DecisionDx-SCC test is designed to stratify risk of regional or distant metastasis in high-risk cutaneous SCC patients,” said Aaron Farberg, M.D., first author, Icahn School of Medicine at Mount Sinai, New York and Arkansas Dermatology Skin Cancer Center, Little Rock, Arkansas. “This manuscript proposes a framework for clinical use of this test, along with current risk stratification tools within established management pathways. The expectation is that the test will enable more informed clinical decisions about adjuvant therapy and other management options.”\n\n\nDisease and Study Background\n\n\n\nApproximately 1 million patients are diagnosed with SCC of the skin in the U.S. each year, and the incidence continues to grow; while the majority of patients have a favorable prognosis, approximately 200,000 patients are identified as high risk.\n\n\nNCCN guidelines for SCC define treatment pathways based on risk of local recurrence or metastasis. For SCC, there are two clinicopathologically defined categories: low risk and high risk. NCCN defines high risk as SCC patients with one or more of several high-risk clinicopathologic features.\n\n\nThe study objective was to integrate gene expression profiling into the management of high-r...